Complete loss of wild-type TP53 in a nontransformed human epithelial cell line is preceded by a phase during which a heterozygous TP53 mutant effectively outgrows the homozygous wild-type cells

Cancer Genetics and Cytogenetics

Volumn 116, Issue 1, 2000, Pages 28-34

  Villadsen, René ^a   Nielsen, Kirsten Vang ^b   Bolund, Lars ^c   Briand, Per ^a  

^a Institute of Biology   (Denmark)

^b AGILENT TECHNOLOGIES   (United States)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALLELE; ARTICLE; CELL LINE; CELL TRANSFORMATION; CELL TYPE; CODON; DELETION MUTANT; EPITHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IN VITRO STUDY; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALLELES; BREAST; CELL DIVISION; CELL LINE; CELL LINE, TRANSFORMED; CHROMOSOMES, HUMAN, PAIR 17; DNA; EPITHELIAL CELLS; FEMALE; FIBROCYSTIC BREAST DISEASE; FLOW CYTOMETRY; GENES, P53; GENOTYPE; HETEROZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0344146428     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(99)00112-0     Document Type: Article

References (22)

1. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
2. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis Cancer Res. 54:1994;4855-4878.
3. Levine A.J., Perry M.E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. The 1993 Walter Hubert Lecture. the role of the p53 tumour-suppressor gene in tumorigenesis Br J Cancer. 69:1994;409-416.
4. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
5. Moyret C., Madsen M.W., Cooke J., Briand P., Theillet C. Gradual selection of a cellular clone presenting a mutation at codon 179 of the p53 gene during establishment of the immortalized human breast epithelial cell line HMT-3522. Exp Cell Res. 215:1994;380-385.
6. Nielsen K.V., Briand P. Cytogenetic analysis of in vitro karyotype evolution in a cell line established from nonmalignant human mammary epithelium. Cancer Genet Cytogenet. 39:1989;103-118.
7. Nielsen K.V., Madsen M.W., Briand P. In vitro karyotype evolution and cytogenetic instability in the non-tumorigenic human breast epithelial cell line HMT-3522. Cancer Genet Cytogenet. 78:1994;189-199.
8. Briand P., Nielsen K.V., Madsen M.W., Petersen O.W. Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Res. 56:1996;2039-2044.
9. Nielsen K.V., Niebuhr E., Ejlertsen B., Holstebroe S., Madsen M.W., Briand P., Mouridsen H.T., Bolund L. Molecular cytogenetic analysis of a nontumorigenic human breast epithelial cell line that eventually turns tumorigenic. validation of an analytical approach combining karyotyping, comparative genomic hybridization, chromosome painting, and single-locus fluorescence in situ hybridization Genes Chromosom Cancer. 20:1997;30-37.
10. Madsen M.W., Lykkesfeldt A.E., Laursen I., Nielsen K.V., Briand P. Altered gene expression of c-myc, epidermal growth factor receptor, transforming growth factor-alpha, and c-erb-B2 in an immortalized human breast epithelial cell line, HMT-3522, is associated with decreased growth factor requirements. Cancer Res. 52:1992;1210-1217.
11. van den Engh G., Trask B., Lansdorp P., Gray J. Improved resolution of flow cytometric measurements of hoechst- and chromomycin-A3-stained human chromosomes after addition of citrate and sulfite. Cytometry. 9:1988;266-270.
12. Pedersen S., Hindkjær J., Brandt C.A., Bolund L., Kølvraa S. Reverse chromosome painting. Choo K.H.A. Methods in Molecular Biology, Vol 33. In Situ Hybridization Protocols. 1994;23-33 Humana Press, Totowa.
13. Chumakov P.M., Almazov V.P., Jenkins J.R. Human p53 gene for transformation related protein p53 (also called transformation-associated protein p53, cellular tumor antigen p53, and non-viral tumour antigen p53). Nucleic Acids Res. 19:1991;4804.
14. Milner J., Medcalf E.A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
15. Srivastava S., Wang S., Tong Y.A., Hao Z.M., Chang E.H. Dominant negative effect of a germ-line mutant p53. a step fostering tumorigenesis Cancer Res. 53:1993;4452-4455.
16. Sun Y., Dong Z., Nakamura K., Colburn N.H. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J. 7:1993;944-950.
17. Brachmann R.K., Vidal M., Boeke J.D. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA. 93:1996;4091-4095.
18. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex. understanding tumorigenic mutations Science. 265:1994;346-355.
19. Strickler J.G., Zheng J., Shu Q., Burgart L.J., Alberts S.R., Shibata D. p53 mutations and microsatellite instability in sporadic gastric cancer. when guardians fail Cancer Res. 54:1994;4750-4755.
20. Law J.C., Whiteside T.L., Gollin S.M., Weissfeld J., El-Ashmawy L., Srivastava S., Landreneau R.J., Johnson J.T., Ferrell R.E. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract. Clin Cancer Res. 1:1995;763-768.
21. Skilling J.S., Sood A., Niemann T., Lager D.J., Buller R.E. An abundance of p53 null mutations in ovarian carcinoma. Oncogene. 13:1996;117-123.
22. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., Finlay C., Levine A.J. Gain of function mutations in p53. Nature Genet. 4:1993;42-46.